Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.66 |
| ▸ | CTSK | P43235 | 7/20 | 0.66 |
| ▸ | CTSB | P07858 | 3/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | MMP9 | P14780 | 2/20 | 0.54 |
| ▸ | MMP8 | P22894 | 2/20 | 0.54 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701014 | 1.00 | CTSS (0.66) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL6162474 | 0.94 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL1764798 | 0.94 | CTSS (0.64) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL4609641 | 0.91 | CTSS (0.55) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL14021756 | 0.91 | CTSS (0.55) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL9929886 | 0.89 | CTSS (0.62) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL8185213 | 0.89 | CTSS (0.62) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL6162882 | 0.87 | CTSS (0.63) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL6162894 | 0.87 | CTSS (0.63) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL1325182 | 0.87 | CTSS (0.72) | CTSSCTSKCTSBCTSLBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| EP-2640689-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012065953-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065953-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | CTSS 357/4885CTSK 252/4885CTSB 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.